Claims
- 1. A method for the treatment of asthma in a patient, comprising administering to the patient a composition comprising delipidated and deglycolipidated M. vaccae cells, wherein the delipidated and deglycolipidated M. vaccae cells comprise less than 10% by weight of lipids.
- 2. The method of claim 1, wherein the composition is administered intranasally.
- 3. The method of claim 1, wherein the composition is administered subcutaneously.
- 4. The method of claim 1, wherein the composition additionally comprises an adjuvant.
- 5. A method for the treatment of asthma in a patient, comprising administering to the patient a composition comprising delipidated and deglycolipidated M. vaccae cells, wherein the delipidated and deglycolipidated M. vaccae cells comprise more than 33% by weight of amino acids.
- 6. The method of claim 5, wherein the composition is administered intranasally.
- 7. The method of claim 5, wherein the composition is administered subcutaneously.
- 8. The method of claim 5, wherein the composition additionally comprises an adjuvant.
REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent application Ser. No. 09/156,181, filed Sep. 17, 1998, which is a continuation-in-part of U.S. patent application Ser. No. 08/996,624, filed Dec. 23, 1997.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09156181 |
Sep 1998 |
US |
Child |
10051643 |
Jan 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08996624 |
Dec 1997 |
US |
Child |
09156181 |
Sep 1998 |
US |